The US Food and Drug Administration (FDA) is planning to fully approve a two-dose coronavirus vaccine from Pfizer-Biontech next Monday, according to The New York Times.
The Food and Drug Administration stated that its new goal is a faster-than-expected timetable for licensing the Pfizer vaccine, and the Food and Drug Administration had previously set an unofficial deadline for approval by Labor Day in the United States, corresponding to next September 6.
According to the American “Insider” website, the approval is expected to provide greater confidence in the vaccine, allowing for a large number of expected vaccination mandates between public and private organizations that were waiting for full authorization before announcing the strong requirements.
The FDA authorized Pfizer's vaccine, along with Moderna and Johnson's, for emergency use late last year.
Health experts are also eager for an FDA-approved vaccine, hoping it will convince some skeptical Americans who have been waiting to get a fully authorized shot for vaccination.
The move will come one week after the Food and Drug Administration updated its vaccine approvals for both Pfizer and Moderna to allow third doses for some immunocompromised people.
Regulators at the Food and Drug Administration on Friday still had a "significant" amount of paperwork and required that negotiations with the company be completed before the final approval process could be completed, according to The Times.
It is worth noting that the “Pfizer” vaccine is a new type of vaccine made from molecules of RNA (mRNAs), which are small parts of genetic material that make human cells produce small parts of the spinal protein of the Corona virus, so that a person has immunity against the real virus when it attacks the body.
Comments
Post a Comment